GS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells.GS87 potently inhibits growth of AML cells in mice with little effect on normal bone marrow cells. GS87 causes terminal differentiation of AML cells.

9-ING-41 is a glycogen synthase kinase-3 inhibitor.9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis[2]. 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker[1]. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM.

BRD1652 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 0.4 nM/4 nM for GSK3α/GSK3β respectively.